Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase
The approval of BRAF and MEK inhibitors has significantly improved treatment outcomes for patients with BRAF-mutated metastatic melanoma. The 3 first-line targeted therapy trials have provided similar results, and thus the identification of predictive biomarkers may generate a more precise basis for...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2020-06-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3526
|
| _version_ | 1818958435481288704 |
|---|---|
| author | Valerie Glutsch Teresa Amaral Claus Garbe Kai-Martin Thoms Peter Mohr Axel Hauschild Bastian Schilling |
| author_facet | Valerie Glutsch Teresa Amaral Claus Garbe Kai-Martin Thoms Peter Mohr Axel Hauschild Bastian Schilling |
| author_sort | Valerie Glutsch |
| collection | DOAJ |
| description | The approval of BRAF and MEK inhibitors has significantly improved treatment outcomes for patients with BRAF-mutated metastatic melanoma. The 3 first-line targeted therapy trials have provided similar results, and thus the identification of predictive biomarkers may generate a more precise basis for clinical decision-making. Elevated baseline lactate dehydrogenase (LDH) has already been determined as a strong prognostic factor. Therefore, this indirect analysis compared subgroups with elevated baseline LDH across the pivotal targeted therapy trials co-BRIM, COMBI-v and COLUMBUS part 1. The Bucher method was used to compare progression-free survival, objective response rate and overall survival indirectly. The results show a non-significant risk reduction for progression in the subgroup with elevated baseline LDH receiving vemurafenib plus cobimetinib compared with dabrafenib plus trametinib and encorafenib plus binimetinib. Although an indirect comparison, these data might provide some guidance for treatment recommendations in melanoma patients with elevated LDH. |
| first_indexed | 2024-12-20T11:25:42Z |
| format | Article |
| id | doaj.art-6304f74fd0074c519cb834b4b18dc5e0 |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-12-20T11:25:42Z |
| publishDate | 2020-06-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-6304f74fd0074c519cb834b4b18dc5e02022-12-21T19:42:22ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572020-06-0110013adv0017410.2340/00015555-35265780Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate DehydrogenaseValerie Glutsch0Teresa AmaralClaus GarbeKai-Martin ThomsPeter MohrAxel HauschildBastian Schilling Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Str. 2, DE-97080 Würzburg, Germany. The approval of BRAF and MEK inhibitors has significantly improved treatment outcomes for patients with BRAF-mutated metastatic melanoma. The 3 first-line targeted therapy trials have provided similar results, and thus the identification of predictive biomarkers may generate a more precise basis for clinical decision-making. Elevated baseline lactate dehydrogenase (LDH) has already been determined as a strong prognostic factor. Therefore, this indirect analysis compared subgroups with elevated baseline LDH across the pivotal targeted therapy trials co-BRIM, COMBI-v and COLUMBUS part 1. The Bucher method was used to compare progression-free survival, objective response rate and overall survival indirectly. The results show a non-significant risk reduction for progression in the subgroup with elevated baseline LDH receiving vemurafenib plus cobimetinib compared with dabrafenib plus trametinib and encorafenib plus binimetinib. Although an indirect comparison, these data might provide some guidance for treatment recommendations in melanoma patients with elevated LDH. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3526 melanoma braf lactate dehydrogenase |
| spellingShingle | Valerie Glutsch Teresa Amaral Claus Garbe Kai-Martin Thoms Peter Mohr Axel Hauschild Bastian Schilling Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase Acta Dermato-Venereologica melanoma braf lactate dehydrogenase |
| title | Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase |
| title_full | Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase |
| title_fullStr | Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase |
| title_full_unstemmed | Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase |
| title_short | Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase |
| title_sort | indirect comparison of combined braf and mek inhibition in melanoma patients with elevated baseline lactate dehydrogenase |
| topic | melanoma braf lactate dehydrogenase |
| url |
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3526
|
| work_keys_str_mv | AT valerieglutsch indirectcomparisonofcombinedbrafandmekinhibitioninmelanomapatientswithelevatedbaselinelactatedehydrogenase AT teresaamaral indirectcomparisonofcombinedbrafandmekinhibitioninmelanomapatientswithelevatedbaselinelactatedehydrogenase AT clausgarbe indirectcomparisonofcombinedbrafandmekinhibitioninmelanomapatientswithelevatedbaselinelactatedehydrogenase AT kaimartinthoms indirectcomparisonofcombinedbrafandmekinhibitioninmelanomapatientswithelevatedbaselinelactatedehydrogenase AT petermohr indirectcomparisonofcombinedbrafandmekinhibitioninmelanomapatientswithelevatedbaselinelactatedehydrogenase AT axelhauschild indirectcomparisonofcombinedbrafandmekinhibitioninmelanomapatientswithelevatedbaselinelactatedehydrogenase AT bastianschilling indirectcomparisonofcombinedbrafandmekinhibitioninmelanomapatientswithelevatedbaselinelactatedehydrogenase |